CoChat
Sign Up
Cited by 97

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Plasma levels of miR-137 and miR-124 are associated with Parkinson’s disease but not with Parkinson’s disease with depression

Li, Na, Pan, Xudong, Zhang, Jingli, Ma, Aijun, Yang, Shaonan, Ma, Juanjuan, Xie, Anmu·2017·Neurological Sciences
DOI 10.1007/s10072-017-2841-9
Open this paper in CoChat — free account

Abstract

MicroRNAs (miRNAs) are a class of small, non-coding RNAs that regulate gene expression at the post-transcriptional level. Recently, it was reported that miR-137, miR-124, and miR-184 were widely expressed in the central nervous system and were vital to neuronal regulation. In this study, we detected the circulating levels of miR-137, miR-124, and miR-184 in PD patients, and explored the potential role of miR-124, miR-137, and miR-184 in the diagnosis of PD. We further described the relationship between these miRNAs and PD with depression (PD-Dep). The study recruited 60 controls and 60 PD patients, which were further divided into two subgroups, PD with depression (PD-Dep, n = 24) and non-depressed group (PD-NDep, n = 36) according to Hamilton Rating Scale for Depression. Plasma levels of miR-137, miR-124, and miR-184 were detected by qRT-PCR. Receiver-operating characteristic (ROC) curve was used to evaluate miR-124 and miR-137 levels as potential diagnostic biomarkers for PD. The results demonstrated that there were no significant differences in levels of miR-184 between PD patients and controls (p > 0.05). However, miR-137 levels were increased significantly for PD patients compared to controls (p 0.05). Thus, plasma levels of miR-137 and miR-124 are associated with Parkinson's disease and might be potential biomarkers of the diagnosis of PD. There were no associations of plasma miR-137 and miR-124 with the severity of PD motor symptoms or PD-Dep.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10072-017-2841-9

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 28

  1. van Rooden SM, Visser M, Verbaan D, Marinus J, van Hilten JJ (2009) Patterns of motor and non-motor features in Parkinson’s disease. J Neurol Neurosurg Psychiatry 80(8):846–850. doi: 10.1136/jnnp.2008.166629 · DOI
  2. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP (2001) Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13(2):187–196. doi: 10.1176/jnp.13.2.187 · DOI
  3. McKinlay A, Grace RC, Dalrymple-Alford JC, Anderson T, Fink J, Roger D (2008) A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson’s disease patients without dementia. Parkinsonism Relat Disord 14(1):37–42. doi: 10.1016/j.parkreldis.2007.05.009 · DOI
  4. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136(2):215–233. doi: 10.1016/j.cell.2009.01.002 · DOI · Paper page
  5. Alvarez-Garcia I, Miska EA (2005) MicroRNA functions in animal development and human disease. Development 132(21):4653–4662. doi: 10.1242/dev.02073 · DOI · Paper page
  6. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, Abeliovich A (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science (New York, NY) 317(5842):1220–1224. doi: 10.1126/science.1140481 · DOI · Paper page
  7. Harraz MM, Dawson TM, Dawson VL (2011) MicroRNAs in Parkinson’s disease. J Chem Neuroanat 42(2):127–130. doi: 10.1016/j.jchemneu.2011.01.005 · DOI
  8. Minones-Moyano E, Porta S, Escaramis G, Rabionet R, Iraola S, Kagerbauer B, Espinosa-Parrilla Y, Ferrer I, Estivill X, Marti E (2011) MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 20(15):3067–3078. doi: 10.1093/hmg/ddr210 · DOI
  9. Cho HJ, Liu G, Jin SM, Parisiadou L, Xie C, Yu J, Sun L, Ma B, Ding J, Vancraenenbroeck R, Lobbestael E, Baekelandt V, Taymans JM, He P, Troncoso JC, Shen Y, Cai H (2013) MicroRNA-205 regulates the expression of Parkinson’s disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet 22(3):608–620. doi: 10.1093/hmg/dds470 · DOI
  10. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513–10518. doi: 10.1073/pnas.0804549105 · DOI · Paper page
  11. Reid G, Kirschner MB, van Zandwijk N (2011) Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 80(2):193–208. doi: 10.1016/j.critrevonc.2010.11.004 · DOI
  12. Ding H, Huang Z, Chen M, Wang C, Chen X, Chen J, Zhang J (2016) Identification of a panel of five serum miRNAs as a biomarker for Parkinson’s disease. Parkinsonism Relat Disord 22:68–73. doi: 10.1016/j.parkreldis.2015.11.014 · DOI · Paper page
  13. Ezzie ME, Crawford M, Cho JH, Orellana R, Zhang S, Gelinas R, Batte K, Yu L, Nuovo G, Galas D, Diaz P, Wang K, Nana-Sinkam SP (2012) Gene expression networks in COPD: microRNA and mRNA regulation. Thorax 67(2):122–131. doi: 10.1136/thoraxjnl-2011-200089 · DOI
  14. Kong Y, Liang X, Liu L, Zhang D, Wan C, Gan Z, Yuan L (2015) High throughput sequencing identifies microRNAs mediating alpha-synuclein toxicity by targeting neuroactive-ligand receptor interaction pathway in early stage of Drosophila Parkinson’s disease model. PLoS One 10(9):e0137432. doi: 10.1371/journal.pone.0137432 · DOI
  15. Cheng LC, Pastrana E, Tavazoie M, Doetsch F (2009) miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat Neurosci 12(4):399–408. doi: 10.1038/nn.2294 · DOI · Paper page
  16. Gehrke S, Imai Y, Sokol N, Lu B (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466(7306):637–641. doi: 10.1038/nature09191 · DOI
  17. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184 · DOI · Paper page
  18. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord Off J Mov Disord Soc 19(9):1020–1028. doi: 10.1002/mds.20213 · DOI
  19. Kim W, Lee Y, McKenna ND, Yi M, Simunovic F, Wang Y, Kong B, Rooney RJ, Seo H, Stephens RM, Sonntag KC (2014) miR-126 contributes to Parkinson’s disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiol Aging 35(7):1712–1721. doi: 10.1016/j.neurobiolaging.2014.01.021 · DOI
  20. Khoo SK, Petillo D, Kang UJ, Resau JH, Berryhill B, Linder J, Forsgren L, Neuman LA, Tan AC (2012) Plasma-based circulating MicroRNA biomarkers for Parkinson’s disease. J Parkinsons Dis 2(4):321–331. doi: 10.3233/jpd-012144 · DOI
  21. Cardo LF, Coto E, de Mena L, Ribacoba R, Moris G, Menendez M, Alvarez V (2013) Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls. J Neurol 260(5):1420–1422. doi: 10.1007/s00415-013-6900-8 · DOI
  22. Wang H, Ye Y, Zhu Z, Mo L, Lin C, Wang Q, Wang H, Gong X, He X, Lu G, Lu F, Zhang S (2016) MiR-124 regulates apoptosis and autophagy process in MPTP model of Parkinson’s disease by targeting to Bim. Brain Pathol 26(2):167–176. doi: 10.1111/bpa.12267 · DOI · Paper page
  23. Jegga AG, Schneider L, Ouyang X, Zhang J (2011) Systems biology of the autophagy-lysosomal pathway. Autophagy 7(5):477–489 · DOI
  24. Vosler PS, Brennan CS, Chen J (2008) Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol 38(1):78–100. doi: 10.1007/s12035-008-8036-x · DOI
  25. McNaught KS, Olanow CW (2006) Protein aggregation in the pathogenesis of familial and sporadic Parkinson’s disease. Neurobiol Aging 27(4):530–545. doi: 10.1016/j.neurobiolaging.2005.08.012 · DOI
  26. Dwivedi Y (2016) Pathogenetic and therapeutic applications of microRNAs in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 64:341–348. doi: 10.1016/j.pnpbp.2015.02.003 · DOI
  27. Rajasethupathy P, Fiumara F, Sheridan R, Betel D, Puthanveettil SV, Russo JJ, Sander C, Tuschl T, Kandel E (2009) Characterization of small RNAs in Aplysia reveals a role for miR-124 in constraining synaptic plasticity through CREB. Neuron 63(6):803–817. doi: 10.1016/j.neuron.2009.05.029 · DOI · Paper page
  28. Vreugdenhil E, Berezikov E (2010) Fine-tuning the brain: MicroRNAs. Front Neuroendocrinol 31(2):128–133. doi: 10.1016/j.yfrne.2009.08.001 · DOI

Cited by

Sorted by citations

See all 97

Metadata

Authors
Li, N., Pan, X., Zhang, J., Ma, A., Yang, S., Ma, J., & Xie, A.
Venue
Neurological Sciences
Publisher
Springer Science and Business Media LLC
Published
2017-02-08
Volume
38
Issue
5
Pages
761-767
ISSN
  • 1590-1874
  • 1590-3478
DOI
10.1007/s10072-017-2841-9
Cited by
97
References
4
Language
en
Licence
www.springer.com/tdm (unspecified)
Funders
  • Qingdao Science and Technology Program (11-2-4-2-(19)-jch)
  • Shandong Science and Technology Program (2012G0021842)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review